NEJM Journal Watch Podcasts: Clinical Conversations

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate

06.27.2022 - By NEJM GroupPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Patients with metastatic breast cancer whose tumors express low levels of HER2 are generally classified and treated as having HER2-negative disease. However, Dr. Shanu Modi of the Memorial Sloan Kettering Cancer Center and a group of international collaborators explored the use of a monoclonal antibody–drug conjugate (trastuzumab–deruxtecan) in patients with disease they classify as HER2-“low.” Compared […]

More episodes from NEJM Journal Watch Podcasts: Clinical Conversations